New chemo cocktail shows promise for rare, aggressive breast cancer
NCT ID NCT02623972
First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 4 times
Summary
This phase 2 study tested a drug called eribulin followed by standard chemotherapy (doxorubicin and cyclophosphamide) as a preoperative treatment for HER2-negative inflammatory breast cancer, a rare and aggressive form of the disease. The goal was to see if this combination could eliminate all signs of cancer in the breast and lymph nodes before surgery. The study enrolled 22 participants and is no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eribulin (Halaven) followed by doxorubicin and cyclophosphamide
- What this could lead to
- If successful, this could point toward a more effective preoperative treatment for a rare and aggressive form of breast cancer.
- What could go wrong
- This is a small, early-phase study with only 22 participants, so results may not apply to all patients. The treatment involves strong chemotherapy with known side effects like heart damage and infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE INFLAMMATORY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New chemo combo aims to shrink aggressive breast cancer before surgery
- Brain scans could spot hidden cancer spread in breast patients
- New hope for nigerian women with aggressive breast cancer: targeted drug combo under study
- Blood clues: can tumor cell clusters predict breast cancer treatment success?
- New drug cocktail shows promise against aggressive breast cancer
- New drug combo shows promise for advanced breast cancer